Vivos Therapeutics Inc Stock Price, News & Analysis

Vivos Therapeutics reported its financial results for Q4 and full year 2022 with revenue of $4.0 million in Q4 and $16.0 million for the full year, compared to $4.4 million and $16.9 million in the previous year. The company completed a capital raise of approximately $7.4 million in January 2023. Gross profit decreased to $2.4 million in Q4, down from $3.1 million in 2021, reflecting increased costs. Vivos also acquired patents from Advanced Facialdontics, enhancing its portfolio for treating sleep disorders. The company aims for revenue growth in 2023 through expanded product offerings and partnerships.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is set to release its fourth quarter and full year 2022 financial results after market close on March 30, 2023. This announcement will be followed by a conference call at 5:00 PM ET to discuss the results and recent milestones. Vivos specializes in medical devices for treating sleep disorders, particularly obstructive sleep apnea (OSA) and snoring, through its proprietary oral appliances. The company has treated over 33,000 patients globally, showcasing the effectiveness of its noninvasive Vivos Method, developed by trained dentists. The company emphasizes its commitment to innovation in the sleep disorder treatment sector.

Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will speak at the 35th Annual ROTH Conference on March 14, 2023, at 1:30 PM PT. The event will be held both virtually and in-person in Dana Point, CA, from March 12-14, 2023. They will participate in a fireside chat and conduct one-on-one meetings with investors. The Vivos Method offers a non-invasive solution for mild-to-moderate obstructive sleep apnea (OSA) and snoring, having treated approximately 31,000 patients globally. More details can be found on their investor relations page.

Vivos Therapeutics (NASDAQ: VVOS) announced the acquisition of patents and product rights from Advanced Facialdontics, enhancing its offerings for treating obstructive sleep apnea (OSA) and related conditions. This includes the Preventive Oral Device (POD^®) for Temporomandibular Joint Dysfunction (TMD) and the Night Block for alleviating traditional treatment downsides. The acquisition broadens Vivos' patent portfolio and aims to open new revenue streams, targeting millions suffering from TMD and Bruxism. CEO Kirk Huntsman emphasized the strategic importance, stating it allows for a complete range of products at competitive prices, enhancing market position.

Vivos Therapeutics (NASDAQ:VVOS) announced that Chairman and CEO Kirk Huntsman will present at the Emerging Growth Conference on February 22, 2023, at 12:35 pm ET. The event invites both institutional and individual investors to participate in a real-time interactive presentation. Vivos focuses on innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea and snoring in adults. The Vivos Method, which has successfully treated around 31,000 patients through trained dentists, offers a noninvasive, nonsurgical solution. The presentation will also be available for replay on Vivos' website for 30 days following the event.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on January 20, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement as per Listing Rule 5550(a)(2). The company previously received a notice on November 3, 2022, for failing to maintain a closing bid price of $1.00 for 30 consecutive business days. By meeting the requirement for a minimum closing bid price of $1.00 for at least 10 consecutive trading days, Vivos is now compliant with all Nasdaq listing standards. The Nasdaq has confirmed that this matter is now closed, marking a significant improvement in Vivos' stock status.

Vivos Therapeutics (NASDAQ: VVOS) has successfully completed a private placement offering, raising $8 million in gross proceeds. After expenses, the company expects net proceeds of approximately $7.4 million to be used for general working capital as it aims to drive revenue growth and control expenses in 2023. The offering included 2 million shares of common stock and warrants for 6.67 million shares at an effective price of $1.20 per share. Vivos promises to file a resale registration statement to allow subsequent trading of these securities.

Vivos Therapeutics (NASDAQ: VVOS) has announced a definitive agreement with an institutional investor to raise approximately $8 million through a private placement at $1.20 per unit. Each unit includes one share of common stock and a warrant exercisable at the same price for five and a half years. After fees and expenses, net proceeds are expected to be $7.5 million. The offering is set to close on January 9, 2023. The securities will not be registered under the Securities Act, and a resale registration statement will be filed within 30 days of closing.

Vivos Therapeutics (NASDAQ: VVOS) announced a significant milestone with the FDA granting clearance for its DNA appliance, marking the first formal recognition of Vivos' proprietary technology for treating mild-to-moderate obstructive sleep apnea (OSA). This 510(k) clearance is Vivos' third FDA approval for its oral devices, enhancing the company's position in the sleep treatment market. Clinical data revealed 28% of patients saw resolution of OSA. The device aims to expand palates and improve airway function, providing a non-invasive alternative to traditional OSA therapies.